CDEK by Data4ThePeople
Drugs
Search by NameFDA Approval TrendsAdvanced SearchFDA Approved Drugs
Organizations
Search by NameOrganization TrendsAdvanced Search
IndicationsMechanismsTrialsFDA Approvals
About
About CDEKGlossaryAdvanced Search GuideSearch by Name
Drugs
Search by NameFDA Approval TrendsAdvanced SearchFDA Approved Drugs
Organizations
Search by NameOrganization TrendsAdvanced Search
IndicationsMechanismsTrialsFDA Approvals
About
About CDEKGlossaryAdvanced Search GuideSearch by Name
← All indications

Lymphadenopathy

Disease of LYMPH NODES which are abnormal in size, number or consistency.

Subtype terms (1)

More specific conditions that are subtypes of Lymphadenopathy in the MeSH hierarchy.

  • Immunoblastic Lymphadenopathy

    1 drug approved

Drugs by status

Phase 3 trials (1)

  • lidocaine

Phase 2 trials (13)

  • autologous t cells
  • bendamustine
  • lenalidomide
  • prednisone
  • valproic acid
  • ofatumumab
  • carboplatin
  • Isatuximab
  • cyclophosphamide
  • cabazitaxel
  • multi-peptide cmv-modified vaccinia ankara vaccine
  • fludarabine
  • rituximab

Other trials (2)

  • ritonavir
  • sitagliptin

Organizations

Organization Involved with Phase 3 Indications (5)

  • Novartis
  • German High-Grade Non-Hodgkin's Lymphoma Study Group
  • Nordic Lymphoma Group
  • Pennsylvania State University
  • University of Goettingen

Organization Involved with Phase 2 Indications (10)

  • Celgene
  • Sanofi
  • GlaxoSmithKline
  • National Institutes of Health (NIH)
  • National Cancer Institute (NCI)
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Southwest Oncology Group
  • Fortress Biotech
  • City of Hope National Medical Center
  • University of Texas at Houston

Organization Involved with Other Experimental Indications (2)

  • Glaxo Wellcome
  • Newport Pharmaceuticals International

ICD-10 crosswalk

  • R59.1 — Generalized enlarged lymph nodes

CDEK

The Clinical Drug Experience Knowledgebase — tracking drugs, sponsoring organizations, and clinical trials from first-in-human testing through approval.

Browse

  • Drugs
  • Organizations
  • Trials

About

  • About CDEK
  • Glossary

Built and maintained by Data4ThePeople.

YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED "AS IS", WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.